Trastuzumab — Mechanism of Action and Use in Clinical Practice
Top Cited Papers
- 5 July 2007
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 357 (1), 39-51
- https://doi.org/10.1056/nejmra043186
Abstract
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.Keywords
This publication has 70 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same RegimenClinical Cancer Research, 2007
- HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric CancerDigestive Diseases and Sciences, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?European Journal of Cancer, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- ErbB2 Pathways in Heart and Neural DiseasesTrends in Cardiovascular Medicine, 2003
- The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunitiesEuropean Journal of Cancer, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987